8-K: Health Catalyst Reports Mixed Q4, FY25 Results Amid Widening Losses

Health Catalyst, a healthcare data and analytics provider, reported mixed financial results for Q4 and full year 2025, with revenue growth but significantly increased net losses and a substantial goodwill impairment.

Summary

• Total revenue for the full year 2025 was $311.1 million, representing a 1% increase year-over-year.
• Total revenue for the fourth quarter of 2025 was $74.7 million, a 6% decrease compared to the same period in 2024.
• GAAP Net loss for the full year 2025 significantly widened to $(178.0) million, a 156% increase from $(69.5) million in 2024.
• GAAP Net loss for the fourth quarter of 2025 was $(91.0) million, a 340% increase from $(20.7) million in Q4 2024.
• Adjusted EBITDA for the full year 2025 increased by 59% to $41.4 million.
• Adjusted EBITDA for the fourth quarter of 2025 increased by 74% to $13.8 million.
• Platform Clients increased to 162 as of December 31, 2025, up from 130 in 2024.
• The Dollar-based Retention Rate (Tech + TEMS) decreased to 93% for the year ended December 31, 2025, from 102% in 2024.
• The company recognized an impairment of goodwill and intangible assets totaling $110.2 million for the full year 2025 and $81.5 million for Q4 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a concerning report due to the substantial increase in net losses, the significant goodwill impairment, and the decline in the dollar-based retention rate, despite some growth in Adjusted EBITDA and client count.

Positives

• Full-year 2025 total revenue increased by 1% to $311.1 million.
• Adjusted EBITDA saw significant growth, increasing by 74% in Q4 2025 to $13.8 million and by 59% for FY 2025 to $41.4 million.
• Gross profit increased by 10% in Q4 2025 to $31.4 million and by 5% for FY 2025 to $120.4 million.
• Adjusted Gross Margin improved to 53.5% in Q4 2025 (from 46.6%) and 51.1% for FY 2025 (from 48.8%).
• Platform Clients increased to 162 in 2025 from 130 in 2024, indicating continued client acquisition.

Negatives

• Q4 2025 total revenue decreased by 6% year-over-year to $74.7 million.
• GAAP Net loss significantly widened by 340% in Q4 2025 to $(91.0) million and by 156% for FY 2025 to $(178.0) million.
• The Dollar-based Retention Rate (Tech + TEMS) declined to 93% in 2025 from 102% in 2024, suggesting potential client churn or reduced spending.
• A substantial impairment of goodwill and intangible assets totaling $110.2 million for the full year 2025 was recognized, indicating a re-evaluation of asset values.
• Cash and cash equivalents decreased substantially from $249.6 million as of December 31, 2024, to $50.8 million as of December 31, 2025.
• Total assets decreased from $858.9 million in 2024 to $502.6 million in 2025.

Risks

• Changes in laws and regulations applicable to the business model.
• Changes in market or industry conditions, regulatory environment, and receptivity to technology and services.
• Results of litigation or a security incident.
• The loss of one or more key clients or partners, clients reducing or eliminating their spend, client churn or down-selling in connection with the migration to Ignite or otherwise.
• Fluctuations in project-based, non-recurring revenue.
• Macroeconomic challenges (including high inflationary and/or high interest rate environments, tariffs, or market volatility and measures taken in response thereto), natural disasters or any new public health crises, and regional or global conflicts (including the conflicts in the Middle East).
• Changes to abilities to recruit and retain qualified team members.

Future Outlook

For the first quarter of 2026, Health Catalyst expects total revenue between $68 million and $70 million, and Adjusted EBITDA between $7 million and $8 million. The company is not providing full-year 2026 guidance at this time due to an ongoing internal strategic and operational review in connection with its CEO transition. The company also anticipates sunsetting the reporting of 'Platform Clients' and 'Dollar-based Retention Rate (Tech + TEMS)' metrics for 2026 and future years, planning to provide new 2026 growth metrics instead.

Management Comments

• "We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million." Ben Albert, CEO.
• "In 2026, we are focused on the future and on positioning Health Catalyst for long-term success." Ben Albert, CEO.
• "As I continue to assess the business, I see both meaningful opportunities and clear areas where we must improve." Ben Albert, CEO.
• "I am confident in the strengths that continue to differentiate this company. Our mission, our people, and our core capabilities, grounded in thousands of improvement projects and billions of dollars in validated impact, provide a solid foundation for delivering meaningful value to our clients and shareholders." Ben Albert, CEO.
• "My priority is to build on these strengths, address our challenges with clarity and discipline, and move the company forward with a renewed sense of focus and execution." Ben Albert, CEO.

Industry Context

StockSavvy.ai notes that Health Catalyst operates in the competitive and evolving healthcare data and analytics sector, which is experiencing increasing demand for efficiency and measurable outcomes. The company's focus on AI-enabled solutions and cloud-based technology aligns with broader industry trends towards digital transformation in healthcare. The decline in dollar-based retention rate, however, suggests potential challenges in client stickiness or competitive pressures, while the increase in platform clients indicates continued market penetration. The significant goodwill impairment could reflect a re-evaluation of market conditions or acquisition performance within the industry.

Stakeholder Impact

• Shareholders: Significant net losses and goodwill impairment could negatively impact investor confidence and share price. The decline in dollar-based retention rate suggests potential future revenue challenges.
• Clients: Increased platform clients indicate continued adoption, but a lower retention rate suggests some clients may be reducing spend or churning.
• Employees: Restructuring costs and workforce reductions (mentioned in footnotes for non-GAAP adjustments) indicate potential impact on employees.

Next Steps

• Host a conference call on March 12, 2026, at 5:00 p.m. E.T. to review results.
• File Annual Report on Form 10-K for the year ended December 31, 2025, on or about March 12, 2026.
• Anticipate sunsetting reporting of 'Platform Clients' and 'Dollar-based Retention Rate (Tech + TEMS)' metrics for 2026 and future years.
• Anticipate providing new 2026 growth metrics in lieu of the sunsetted metrics.
• Continue an ongoing internal strategic and operational review in connection with the CEO transition.

Key Dates

Recommendation

The substantial increase in net losses, significant goodwill impairment, and declining dollar-based retention rate point to underlying operational challenges and a deteriorating financial position. While Adjusted EBITDA improved, the GAAP losses and asset write-downs are major red flags. The lack of full-year guidance due to a strategic review further adds to uncertainty, suggesting a need for a fundamental re-evaluation of the business model. Investors should consider selling given these negative indicators and the high level of uncertainty.

Keywords

Healthcare technology, Data analytics, SEC filing, HCAT, Financial results, Q4 2025, FY 2025, Adjusted EBITDA, Net loss, Revenue, Healthcare IT, Goodwill impairment, Client retention